Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
- Mechanism
- Curator reviewed
SCIO-469 inhibits p38 kinase, a stimulatory modulator of pro-inflammatory factors including tumor necrosis factor-alpha (TNFa), interleukin-1 (IL-1), and cyclooxygenase-2 (COX-2), all of which are known to contribute to both symptoms and disease progression in patients with Rheumatoid Arthritis (RA). Existing protein-based products that antagonize TNFa have been shown to markedly relieve the symptoms and retard the progression of RA. It also has the potential for additional benefits associated with its inhibition of IL-1 and COX-2.
- Primary indication
- Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.Curator reviewed
- Formula / weight
- C27H30ClFN4O3 · 513.004 g/mol (avg)
- Code names
- SCIO-469
Resolves to
ZMELOYOKMZBMRB-DLBZAZTESA-NSMILES[H][C@]1(C)CN(C(=O)C2=C(Cl)C=C3N(C)C=C(C(=O)C(=O)N(C)C)C3=C2)[C@]([H])(C)CN1CC1=CC=C(F)C=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Talmapimod, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account